Application of Phage Display Technology to Cancer Research

Authors: Yip Y.L.; Ward R.L.

Source: Current Pharmaceutical Biotechnology, Volume 3, Number 1, March 2002 , pp. 29-43(16)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Despite years of international effort, cancer remains a major cause of death in developed countries, claiming more than 500 000 lives per year in the United States alone. Recombinant DNA technology and high throughput screening methods have recently increased the pace of cancer research. In this review, we will examine the impact and contribution of phage display technology to this area of research. As a biological combinatorial system, the strength of phage display lies in its flexibility and its ability to efficiently study protein-protein interactions. The technology has also facilitated the discovery of molecules that have potential roles in the diagnosis and treatment of cancer.

Keywords: Phage Display; protein-protein interactions; glioblastomas; cDNA libraries; immunogenic; anti-ErbB-2 internalising Mab; Melanoma; immunotherapeutic agents; Cytotoxic T lymphocytes; Monoclonal antibody

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201023378472

Publication date: 2002-03-01

More about this publication?

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.